Diagnosis of Gestational Diabetes in Eldoret, Kenya

December 2, 2016 updated by: Sonak Pastakia, Indiana University

Establishing the Prevalance and Accuracy of Different Diagnostic Techniques for Gestational Diabetes in the Resource-constrained Setting of Eldoret, Kenya

The objective of this study is to determine the most appropriate and effective approach for the diagnosis of gestational diabetes mellitus (GDM) among pregnant women receiving focused antenatal care at Moi Teaching and Referral Hospital (MTRH). This will be done through performing a random blood sugar, fasting blood sugar, 1 hr/2hr glucose tolerance test, and HbA1c on all participants who meet eligibility criteria and provide written, informed consent. The specific research question is: what is the most appropriate screening and diagnostic strategy for patients receiving antenatal care at MTRH?

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

1.0 Background

Worldwide, 70 million women in the reproductive age have diabetes or impaired glucose tolerance placing them at risk of complications of hyperglycemia in pregnancy. The global prevalence rates of gestational diabetes mellitus (GDM) vary from between 12% and 14% depending on the population studied.(1,2) The estimated prevalence of GDM has been reported in Western (11.6%) and South Africa (3.8% - 8.8%) but because of the lack of published results and consistency in diagnosis, treatment, and outcomes in Eastern Africa, the extent of the problem of GDM is unknown in Kenya.(2) Estimates from these studies in sub-Saharan Africa (SSA) reveal a widely variable prevalence ranging from 2.4% to 14% with different methodologies and populations of different risk categories. This lack of focused investigation on GDM in Kenya is of concern as preliminary,unpublished data from the Kenyan Global Network Study on birth outcomes suggests that 5.5 % of birth weights in Western Kenya are greater than 4000g, suggesting a substantial potential burden of diabetes mellitus (DM) or GDM in this population.(3) Maternal hyperglycemia during pregancy predisposes the offspring to glucose intolerance in the future by fetal programming. (1,4,5) This vicious cycle can influence and perpetuate the incidence and prevalence of diabetes in any population. Infants born to mothers with diabetes experience double the risk of serious injury at birth, triple the likelihood of caeserean delivery and quadruple the incidence of newborn intensive care unit admissions.(6-8) These maternal, fetal, and neonatal morbidities attributable to diabetes in pregnancy can be prevented with early diagnosis of DM and effective treatment. Within the landscape of care in Western Kenya, pregnancy may be the only time a woman presents for medical care. Therefore, pregnancy is an opportune time to have a receptive audience to screen for possible pregestational diabetes, promote health education, and diagnose glucose intolerance as the woman transitions beyond the postnatal period.

MTRH is the second largest referral hospital in Kenya and serves as a referral center for the whole of Western Kenya. Although access to healthcare is limited in rural areas of Kenya, the Antenatal Clinic at the hospital serves up to 12,000 new mothers annually. Screening for GDM in the antenatal clinic at MTRH is currently limited to a routine urinalysis for glucosuria. Sutherland and colleagues found that 11% of an unselected obstetric population of 1418 women had random glucosuria. However, only 1% of those with glucosuria had an abnormal glucose tolerance test.9 Glucosuria is common in pregnancy and has not been shown to correlate with the diagnosis of GDM.

2.0 Rationale and Specific Aims

The use of a routine urinalysis as a screening strategy for GDM is not consistent with any national or international guidelines.(10-13) There is currently no consensus on the best method to screen for GDM in rural settings lacking infrastructure for venous testing. There are a variety of testing strategies which have been predominantly tested in resource-rich settings and are now used as the standard of care worldwide. Unfortunately, these testing strategies have not been validated or implemented in resource-constrained settings like those existing in Western Kenya.(2) In the United Kingdom, there is a general lack of consensus; most centers employ the 75g glucose tolerance test (Sensitivity 29% and Specificity 96% - these values are for the 75g 2hr postprandial random blood sugar and not the glucose tolerance test), others adopt a two-stage protocol, starting with 50g screen, to be followed, if abnormal, with 75-g glucose tolerance test. Also, according to the WHO criteria and ADA guidelines for GDM diagnosis, a random blood sugar >11mmol/L (198 mg/dL) or a fasting blood sugar >7.0mmol/L (126 mg/dL) meets the threshold for diagnosis of GDM.(12) Because of this uncertainty, the International Association of Diabetes and Pregnancy Study Groups (IADPSG) has recently helped provide greater clarity to this issue by issuing suggested guidelines for diagnosing both gestational diabetes and overt diabetes in pregnancy. They recommend the 75gm oral glucose tolerance test and the cutpoints derived from the Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) study for all patients receiving GDM screening.

As suggested in the IADPSG guidelines and an emerging body of literature, there is growing support for the utilization of the glycosylated hemoglobin (HbA1c) in diagnosing diabetes. (16) Lipska and colleagues report that women and people of African-American ethnicity are more likely to be identified with dysglycemia using HgbA1c than by fasting blood glucose. A notable weakness of this study is that it was performed in adults age 70-79 and thus it is unlcear whether HbAIC can be used as a diagnostic tool in pregnancy. None of the currently available studies evaluating the use of A1c's for GDM have included African women.(17-20) Several studies have also raised concerns about the accuracy of HbA1c in African populations as the HbA1c results tend to be higher than those seen in other populations.(21-23) Because of the various approaches that are currently being proposed by the IADPSG guidelines, there is still considerable debate over the appropriate test to employ as they recommend performing a fasting blood sugar, HbA1c, or random plasma glucose on all women during their first prenatal visit. If a diagnosis of diabetes is not made during this assessment, it is recommended that a 75g oral glucose tolerance test is performed during the 24th to 28th week of the pregnancy to test for GDM. By combining the results of several studies they have also analyzed the additive benefits of combining different strategies. Through this investigation they have concluded that analyzing fasting blood sugars alone enabled them to identify 8.3% of the evaluable population, while the 1 hour glucose measurement identified another 5.7%, and 2 hour glucose measurement identified an additional 2.1%. One major limitation of this investigation, however, was that the cohort did not include patients reflective of the rural SSA population the investigators on this trial serve in Western Kenya. This theme is illustrated throughout this background as there is a deficiency of published results regarding GDM in SSA populations.(10) The IADPSG diagnosis approach also assumes that the vast majority of expectant mothers will have frequent contacts with the healthcare system including early prenatal visits and subsequent visits throughout the pregnancy. This trend is not commonly seen in SSA as a large proportion of expectant mothers deliver at home or have only minimal contact with the healthcare system.(2) Because of these dynamics, there is a clear need to simplify the diagnostic approach for GDM while also assessing the relative utility of each of the testing strategies (ie. random blood sugar, fasting blood sugar, 1 hr/2hr glucose tolerance test, and HbA1c).

Through this proposal, the investigators hope to take the first step towards addressing GDM in this setting by assessing the relative effectiveness of point of care testing strategies, in comparison to the gold standard approach of using the 75gm oral glucose tolerance test in a representative understudied population.

Study Type

Observational

Enrollment (Actual)

935

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Sampling Method

Non-Probability Sample

Study Population

This is a prospective cohort study that will be conducted at Moi Teaching and Referral Hospital, Mediheal Hospital, and Uashin Gishu District Hospital Antenatal Clinic in western Kenya

Description

Inclusion criteria:

  • All pregnant women at 24-32 weeks gestation
  • Singleton pregnancies

Exclusion Criteria:

  • Pre-existing diagnosis of diabetes
  • Participants < 18 years of age
  • On medications that affect glucose control
  • Unable to complete the study protocol
  • Unable to provide informed consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Pregnant women between 24 to 32 weeks

Pregnant women with a singleton pregnancy who presented to care between 24 -32 weeks of their pregnancy were included in this study.

All patients enrolled in the study will receive a random point of care blood sugar, point of care and venous fasting blood sugar, point of care and venous 1 hr/2hr glucose tolerance test, and point of care and venous HbA1c.
Procedure: Point of care and venous screening

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Prevalence of Gestational Diabetes via venous 75 gm oral glucose tolerance test
Time Frame: Measured between 24-32 weeks of pregnancy
We determined prevalence of gestational diabetes by utilizing the gold standard testing strategy recommended by IADPSG. This includes the completion of a venous fasting blood sugar, provision of a 75 gm glucose, 1 hr post prandial venous glucose assessment, 2 hour post prandial venous glucose assessment. We recruited 935 patients of which 616 patients returned for the venous testing and completed these tests.
Measured between 24-32 weeks of pregnancy

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Specificity, Sensitivity, positive predictive value, and negative predictive value of alternative point of care screening strategies
Time Frame: Measured between 24-32 weeks of pregnancy

On day 1, a capillary blood sample was obtained to perform a point of care (POC) random blood glucose test and glycated hemoglobin. A 50gm glucose load was then administered capillary blood samples were collected after 1-hr All participants were then expected to return the next day (or within 1 week for those unable to follow-up immediately) after having fasted overnight for ≥ 8 hours.

Day 2 testing procedures included recommended IADPSG testing alongside the analogous POC tests. Capillary and venous blood samples for measurement of POC and plasma fasting glucose, venous HbA1c and a complete blood count with differential was performed. A 75gm glucose load was then administered with capillary and venous blood samples collected at 1-hr and 2-hrs for measurement of POC and plasma glucose levels.

The sensitivity, specificity, NPV and PPV of each screening strategy was determined using 2 by 2 matrices with the IADPSG criteria for the venous 75gm OGTT as the gold standard reference.
Measured between 24-32 weeks of pregnancy

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Indiana University

Collaborators

Indiana Clinical and Translational Sciences Institute
Purdue University
Moi University

Investigators

  • Principal Investigator: Sonak D Pastakia, PharmD, MPH, Purdue University, Moi University, Indiana University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2012

Primary Completion (ACTUAL)

December 1, 2015

Study Completion (ACTUAL)

April 1, 2016

Study Registration Dates

First Submitted

November 29, 2016

First Submitted That Met QC Criteria

November 29, 2016

First Posted (ESTIMATE)

December 1, 2016

Study Record Updates

Last Update Posted (ESTIMATE)

December 5, 2016

Last Update Submitted That Met QC Criteria

December 2, 2016

Last Verified

December 1, 2016

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 1205008671

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

There is no need to send out IPD and only de-identified data was analyzed

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diabetes, Gestational

Clinical Trials on Point of care and venous screening

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guatemala

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe